CHADDS FORD, Pa. — Endo Pharmaceuticals has ended its research program and collaboration with Grunenthal.
The announcement comes shortly after the companies revealed their mid-stage clinical trial results for axomadol — designed to treat chronic low back pain — did not meet the predetermined endpoint.
Endo licensed exclusive rights to develop and market axomadol in the United States and Canada from Grunenthal in February 2009.
"As a leader in the field of pain management, Endo remains committed to the development and commercialization of pain therapeutics," Endo Pharmaceuticals EVP research and development Ivan Gergel said. "We have appreciated the opportunity to collaborate with Grunenthal on this program and they have been an excellent partner."